AtriCure, Inc. 8-K

What Happened

• On January 9, 2026, AtriCure, Inc. and its subsidiary AtriCure, LLC entered into a First Amendment to their JPMorgan‑led Credit Agreement. The amendment extends the term of the asset‑based revolving credit facility (ABL Facility) by three years, reduces the overall interest rate on loans under the ABL Facility, and eliminates the minimum utilization financial covenant. The ABL Facility provides up to $125 million in revolving commitments (with an option to increase by up to $40 million to a $165 million cap), includes up to $5 million available for letters of credit, and permits swingline loans at the Administrative Agent’s discretion. The facility is secured by a first‑priority perfected security interest in the Borrowers’ assets and is guaranteed by the Borrowers and each direct and indirect Material Domestic Subsidiary; at closing the Borrowers were the only Guarantors. The ABL Facility is intended to fund working capital and general corporate purposes.
• On January 12, 2026, AtriCure furnished a press release with preliminary financial results for the quarter and full year ended December 31, 2025 (filed as Exhibit 99.1).

Key Details

• Date of amendment/closing: January 9, 2026.
• ABL Facility size: up to $125 million, plus option to increase up to $40 million (total up to $165 million).
• Letters of credit: up to $5 million available within the ABL Facility.
• Material changes: three‑year term extension, reduced interest rate, removal of minimum utilization covenant; facility secured by first‑priority liens; guarantees from Borrowers and Material Domestic Subsidiaries (Borrowers only as of closing).
• Press release: preliminary Q4 and FY2025 results announced January 12, 2026 (Exhibit 99.1).

Why It Matters

• The amendment extends the company’s committed credit runway and lowers borrowing costs, which can improve near‑term liquidity and reduce cash interest expense compared with prior terms. Removing the minimum utilization covenant gives the company more flexibility in how it uses the facility. Because the ABL is secured by company assets, it affects the priority and structure of AtriCure’s borrowings.
• Investors should review the January 12 press release (Exhibit 99.1) for the preliminary Q4 and full‑year financial results to assess recent operating performance alongside the updated credit terms.